Intrahepatic Cholangiocarcinoma: A Malignancy of Increasing Importance

Journal of the American College of Surgeons

Volumn 207, Issue 4, 2008, Pages 594-603

  Hammill, Chet W ^a   Wong, Linda L ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

BILE DUCT CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHOLANGIOGRAPHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; HUMAN; INCIDENCE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MONOTHERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; ULTRASOUND;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; NEOPLASM STAGING; RISK FACTORS;

EID: 52949153589     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.04.031     Document Type: Review

References (80)

1. Malhi H., and Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatology 45 (2006) 856-867
2. Foucar E., Kaplan L.R., Gold J.H., et al. Well-differentiated peripheral cholangiocarcinoma with unusual clinical course. Gastroenterology 77 (1979) 347-353
3. Nakajima T., Kondo Y., Miyazaki M., and Okui K. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol 19 (1988) 1228-1234
4. Pitt H.A., Dooley W.C., Yeo C.J., and Cameron J.L. Malignancies of the biliary tree. Curr Probl Surg 32 (1995) 36-70
5. Nakeeb A., Pitt H.A., Sohn T.A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224 (1996) 463-473
6. In: Fritz A. (Ed). International classification of diseases for oncology. 3rd edition (2000), World Health Organization, Geneva, Switzerland
7. Welzel T.M., McGlynn K.A., Hsing A.W., et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Nat Cancer Inst 98 (2006) 873-875
8. Lim J.H., and Park C.K. Pathology of cholangiocarcinoma. Abd Imaging 29 (2004) 540-547
9. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. (2000), Kanehara, Tokyo
10. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2002) 74-108
11. SEER Cancer Statistics Review 1975-2004. US National Institute of Health. http://www.SEER.cancer.gov Accessed May 6, 2008
12. Centers for Disease Control and Prevention, Department of Health and Human Services, National Program of Cancer Registries, US Cancer Statistics 2004. http://www.apps.nccd.cdc.gov Accessed April 2008
13. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2 (2002) 10-15
14. Khan S.A., Taylor-Robinson S.D., Toledano M.B., et al. Changing international trends in mortality rates of liver, biliary and pancreatic tumors. J Hepatology 37 (2002) 806-813
15. Wood R., Brewster D.H., Fraser L.A., et al. Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk?. Insights from cancer registry data in Scotland. Eur J Cancer 39 (2003) 2087-2092
16. Taylor-Robinson S.D., Toledano M.B., Arora S., et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48 (2001) 816-820
17. Shaib Y.H., Davila J.A., McGlynn K., and El-Serag H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatology 40 (2004) 472-477
18. McLean L., and Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 26 (2006) 1047-1053
19. McGlynn K.A., Tarone R.E., and El-Serag H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15 (2006) 1198-1203
20. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
21. Chapman R.W. Risk factors for biliary tract carcinogenesis. Ann Oncol 10 (1999) 308-311
22. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (2002) 321-327
23. Voyles C.R., Smadja C., Shands W.C., and Blumgart L.H. Carcinoma in choledochal cysts: age-related incidence. Arch Surg 118 (1983) 986-988
24. Dayton M.T., Longmire Jr. W.P., and Tompkins R.K. Caroli's disease: a premalignant condition?. Am J Surg 145 (1983) 41-48
25. Yamato T., Sasaki M., Hoso M., et al. Intrahepatic cholangiocarcinoma arising in congenital hepatic fibrosis: report of an autopsy case. J Hepatol 28 (1998) 717-722
26. Parkin D.M., Srivatankakul P., Khlat M., et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 48 (1991) 323-328
27. Watanapa P., and Watanapa W.B. Liver fluke-associated cholangiocarcinoma. Br J Surg 89 (2002) 962-970
28. Khan S.A., Davidson B.R., Goldin R., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 (2002) 1-9
29. Shaib Y.H., El-Serag H.B., Davila J.A., et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128 (2005) 620-626
30. Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5 (2007) 1221-1228
31. Welzel T.M., Mellemkjaer L., Gloria G., et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 120 (2007) 638-641
32. Shaib Y.H., El-Serag H.B., Nooka A.K., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 102 (2007) 1016-1021
33. Donato F., Gelatti U., Tagger A., et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 12 (2001) 959-964
34. Yamamoto S., Kubo S., Hai S., et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 95 (2004) 592-595
35. Gastelis N.K., Tepetes K., Loukopoulos A., et al. Hepatitis B virus and intrahepatic cholangiocarcinoma. Cancer Invest 25 (2007) 55-58
36. Qu Z.L., Zou S.Q., Cui N.Q., et al. Upregulation of human telomerase reverse transcriptase mRNA expression by in vitro transfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells. World J Gastroenterol 11 (2005) 5627-5632
37. Liu X., Zou S., and Qiu F. Expression of nuclear factor kappa B in hepatitis C virus core gene transfected cholangiocarcinoma cells. Chin Med J 115 (2002) 998-1001
38. Khan S.A., Thomas H.C., Toledano M.B., et al. p53 mutations in human cholangiocarcinoma: a review. Liver Int 25 (2005) 704-716
39. Rizzi P.M., Ryder S.D., Portmann B., et al. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 38 (1996) 265-268
40. Obama K., Ura K., Li M., et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 41 (2005) 1339-1348
41. Okabayashi T., Yamamoto J., Kosuge T., et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 92 (2001) 2374-2383
42. Chen M.F., Jan Y.Y., Jeng L.B., et al. Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 6 (1999) 136-141
43. DeOliviera M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one year experience with 564 patients at a single institution. Ann Surg 245 (2007) 755-762
44. Paik K.Y., Jung J.C., Heo J.S., et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma?. J Gastroenterol Hepatol 23 (2008) 766-770
45. Inoue K., Makuuchi M., Takayama T., et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127 (2000) 498-505
46. Nakeeb A., Pitt H.A., Sohn T.A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar and distal tumors. Ann Surg 224 (1996) 463-473
47. Nichols J.C., Gores G.J., LaRusso N.F., et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68 (1993) 874-879
48. Patel A.H., Harnois D.M., Kelee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma without primary sclerosing cholangitis. Am J Gastroenterol 95 (2000) 204-207
49. Singh P., and Patel T. Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Current Opin Gastroenterol 22 (2006) 294-299
50. Levy C., Lymp J., Angulo P., et al. The value of serum Ca 19-9 in patients with primary sclerosing cholangitis. Dig Dis Sci 50 (2005) 1734-1740
51. Takamori R., Wong L.L., Dang C., et al. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?. Liver Transpl 6 (2000) 67-72
52. Huang G.T., Sheu J.C., Yang P.M., et al. Ultrasound guided cutting biopsy for the diagnosis of hepatocellular carcinoma-a study based on 420 patients. J Hepatol 25 (1996) 334-338
53. Durand F., Regimbeau J.M., Belghiti J., et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35 (2001) 254-258
54. Kim S.H., Lim H.K., Lee W.J., et al. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5 gauge automated biopsy gun. Abdom Imaging 25 (2000) 246-250
55. Chaupoutot C., Perney P., Fabre D., et al. Needle-tract seeding after ultrasound guided puncture of hepatocellular carcinoma: A study of 150 patients. Gastroenterol Clin Biol 23 (1999) 552-556
56. Greene F.L., Page D.L., Fleming I.D., and Fritz A. AJCC cancer staging manual. 6th edition (2002), Lippincott Raven Publishers, Philadelphia
57. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001) 1353-1357
58. Nathan H., Pawlik T.M., Wolfgang C.L., et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11 (2007) 1488-1496
59. Schlinkert R.T., Nagorney D.M., Van Heerden J.A., and Adson M.A. Intrahepatic cholangiocarcinoma: clinical aspects, pathology and treatment. HPB Surg 78 (1992) 727-731
60. Yamamoto J., Kosuge T., Takayama T., et al. Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 111 (1992) 617-622
61. Jan Y.Y., Jeng L.B., Hwang T.L., et al. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology 43 (1996) 614-619
62. Valverde A., Bonhomme N., Farges O., et al. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 6 (1999) 122-127
63. Madariaga J.R., Iwatsuki S., Todo S., et al. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 227 (1998) 70-79
64. Casavilla F.A., Marsh J.W., Iwatsuki S., et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 185 (1997) 429-436
65. Shimada K., Sano T., Sakamoto Y., et al. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: A comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 31 (2007) 2016-2022
66. Weber S.M., Jarnagin W.R., Klimstra D., et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193 (2001) 384-391
67. Pichlmayr R., Lamesch P., Weimann A., et al. Surgical treatment of cholangiocellular carcinoma. World J Surg 19 (1995) 83-88
68. Aishima S., Kuroda Y., Nishihara Y., et al. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol 7 (2007) 1059-1067
69. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 16 suppl 2 (2005) ii93-ii96
70. Glimelius B. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7 (1996) 593-600
71. Kirchhoff T., Zender L., Merkesdal S., et al. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 11 (2005) 1091-1095
72. Herber S., Otto G., Schneider J., et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 30 (2007) 1156-1165
73. Burger I., Hong K., Schulick R., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16 (2005) 353-361
74. Cantore M., Mambrini A., Fiorentini G., et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 103 (2005) 1402-1407
75. Vogl T.J., Schwarz W., Eichler K., et al. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 132 (2006) 745-755
76. Tanaka N., Yamakado K., Nakatsuka A., et al. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience. Eur J Radiol 41 (2002) 42-48
77. Pitt H.A., Nakeeb A., Abrams R.A., et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221 (1995) 788-797
78. Davila J.A., Morgan R.O., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 (2004) 1372-1380
79. Nguyen T.T., Gildengorin G., Truong A., and McPhee S.J. Factors influencing physicians' screening behavior for liver cancer among high-risk patients. J Gen Intern Med 22 (2007) 523-526
80. Chalasani N., Said A., Ness R., et al. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 94 (1999) 2224-2229